Guillaume Cartron

Guillaume Cartron

UNVERIFIED PROFILE

Are you Guillaume Cartron?   Register this Author

Register author
Guillaume Cartron

Guillaume Cartron

Publications by authors named "Guillaume Cartron"

Are you Guillaume Cartron?   Register this Author

100Publications

3656Reads

34Profile Views

The therapeutic effectiveness of Lu-lilotomab in B-cell non-Hodgkin lymphoma involves modulation of G2/M cell cycle arrest.

Leukemia 2019 Dec 13. Epub 2019 Dec 13.

Institut de Recherche en Cancérologie de Montpellier (IRCM), Inserm U1194, Université de Montpellier, Institut Régional du Cancer de Montpellier (ICM), Montpellier, F-34298, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41375-019-0677-4DOI Listing
December 2019

Adverse reactions related to brentuximab vedotin use: A real-life retrospective study.

Therapie 2019 Jun 20;74(3):343-346. Epub 2018 Jul 20.

Department of medical pharmacology and toxicology, Montpellier university hospital, 34295 Montpellier, France; Laboratory of biostatistics, epidemiology and public health (EA 2415), faculty of medicine, university of Montpellier, 34295 Montpellier, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.therap.2018.07.004DOI Listing
June 2019

Infusion-related reactions to rituximab: frequency, mechanisms and predictors.

Expert Rev Clin Immunol 2019 04 11;15(4):383-389. Epub 2019 Jan 11.

a Département d'Hématologie Clinique , CHRU de Montpellier , Montpellier , France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/1744666X.2019.1562905DOI Listing
April 2019

Post-treatment positron emission tomography-computed tomography is highly predictive of outcome in Plasmablastic lymphoma.

Eur J Nucl Med Mol Imaging 2018 09 20;45(10):1705-1709. Epub 2018 Apr 20.

Department of Hematology, University Hospital of Montpellier, UMR CNRS 5235, Montpellier, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00259-018-4020-5DOI Listing
September 2018

Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma.

N Engl J Med 2018 09;379(10):934-947

From Université Lille, Centre Hospitalier Universitaire (CHU), Groupe de Recherche sur les formes Injectables et les Technologies Associées, Lille (F.M.), CHU Régional de Nancy, Service d'Hématologie, Vandoeuvre lès Nancy (P.F.), Institut Paoli-Calmettes (R.B.) and Department of Pathology, Institut Paoli-Calmettes, Centre de Recherche en Cancerologie de Marseille, INSERM, Centre National de la Recherche Scientifique, Aix-Marseille Université (L.X.), Marseille, Centre Henri Becquerel, Unité 1245 and Département d'Hématologie, Université de Rouen, Rouen (H.T.), Institut d'Hématologie de Basse Normandie, Caen (C.F.), CHU Le Bocage Service d'Hématologie Clinique, Dijon (R.-O.C.), Hôpital Henri Mondor Unité Hémopathies Lymphoïdes, Créteil (C.H.), Centre Hospitalier Départemental Vendée Service d'Onco-Hématologie, La Roche sur Yon (H.M.), Institut Universitaire du Cancer de Toulouse Oncopole Service d'Hématologie, Toulouse (L.Y.), CHU Bordeaux, Service d'Hématologie, Bordeaux (K.B.), Hôpital Saint Louis Service d'Onco-Hématologie, Paris (P.B.), Gustave Roussy Cancer, Villejuif (V.R.), Centre Hospitalier Annecy Genevois Service, Annecy (N.D.), CHU de Nantes-Hôtel Dieu Service d'Hématologie Clinique, Centre de Recherche en Cancerologie et Immunologie, INSERM, Centre National de la Recherche Scientifique, Université de Nantes, Nantes (S.L.G.), Centre Hospitalier Métropole Savoie Service Hématologie, Chambery (G.M.P.), Department of Hematology, CHU Montpellier, University of Montpellier, Montpellier (G.C.), and Hospices Civils de Lyon, Centre Hospitalier Lyon-Sud, University of Lyon, Pierre-Benite (G.A.S.) - all in France; the Department of Lymphoma and Myeloma, University of Texas M.D. Anderson Cancer Center, Houston (N.H.F.); the Department of Medicine, Memorial Sloan Kettering Cancer Center, New York (M.L.P.); the Department of Medicine, Division of Medical Oncology, University of Washington, Seattle (E.N.L.); Sarah Cannon Research Institute-Tennessee Oncology, Nashville (I.W.F.); Washington University School of Medicine, Siteman Cancer Center, St. Louis (N.L.B.); the Department of Hematology, Hospital Universitario de Salamanca and Instituto de Investigación Biomédica de Salamanca, Centro de Investigación Biomédica en Red de Cáncer, Salamanca (A.M.G.-S.), and the Department of Hematology, Hospital Clinic de Barcelona, Barcelona (A.L.-G.) - both in Spain; CHU de Québec, Hôpital de l'Enfant-Jésus, Quebec (J.-F.L.), and British Columbia Cancer Centre for Lymphoid Cancer, University of British Columbia, Vancouver (L.H.S.) - both in Canada; the Department of Hematology and Oncology, Tokai University Hospital, Kanagawa, Japan (K.A.); Instituto Português de Oncologia Lisboa Francisco Gentil Departamento de Hematologia, Lisbon (M.G.S.); the Department of Hematology, CHU Université Catholique de Louvain Namur, Yvoir (M.A.), and the Department of Hematology, Ziekenhuis Netwerk Antwerpen Stuivenberg, Antwerp (P.Z.) - both in Belgium; the Department of Hematology, National Cancer Center Hospital, Tokyo, Japan (K.T.); and Celgene, Summit, NJ (D.L., J.W.).

View Article

Download full-text PDF

Source
http://www.nejm.org/doi/10.1056/NEJMoa1805104
Publisher Site
http://dx.doi.org/10.1056/NEJMoa1805104DOI Listing
September 2018

Targeting the SUMO Pathway Primes All- Retinoic Acid-Induced Differentiation of Nonpromyelocytic Acute Myeloid Leukemias.

Cancer Res 2018 05 27;78(10):2601-2613. Epub 2018 Feb 27.

Equipe Labellisée Ligue contre le Cancer, Institut de Génétique Moléculaire de Montpellier, University of Montpellier, CNRS, Montpellier, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-17-3361DOI Listing
May 2018

Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia.

N Engl J Med 2018 Mar;378(12):1107-1120

From the Peter MacCallum Cancer Centre, Royal Melbourne Hospital, and University of Melbourne, Melbourne, VIC (J.F.S.), and the John Curtin School of Medical Research, Australian National University, Canberra, ACT (J.D.) - all in Australia; the University of California School of Medicine, San Diego (T.J.K.), and Genentech, South San Francisco (E.A.P., Y.L., M. Mobasher) - both in California; University Hospital Cologne and the Center for Integrated Oncology Cologne-Bonn, Cologne, Germany (B.E.); St. James's University Hospital, Leeds (P.H.), and F. Hoffmann-La Roche, Welwyn Garden City (M.B., K.H.) - both in the United Kingdom; Segal Cancer Center, Lady Davis Institute, Jewish General Hospital, Montreal (S.A.), and the Departments of Medicine and Oncology, University of Calgary, Calgary, AB (C.O.) - all in Canada; Memorial Sloan Kettering Cancer Center, New York (J.G.); the Department of Hematology, Medical University of Lodz and Copernicus Memorial Hospital, Lodz, Poland (T.R.); Hospital Universitario 12 de Octubre, Madrid (J.D.S.); Medical University of Vienna, Department of Medicine I, Division of Hematology and Hemostaseology, Vienna (U.J.); the Department of Hematology, Centre Hospitalier Universitaire Montpellier, Montpellier, France (G.C.); the Department of Onco-Hematology, Division of Hematology, Niguarda Cancer Center, Niguarda Hospital, Milan (M. Montillo); AbbVie, North Chicago, IL (R.H.); and the Department of Hematology, Cancer Center Amsterdam, Academic Medical Center, Amsterdam (A.P.K.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1713976DOI Listing
March 2018

Clinical and microbiological characteristics of the infections in patients treated with rituximab for autoimmune and/or malignant hematological disorders.

Autoimmun Rev 2018 Feb 24;17(2):115-124. Epub 2017 Nov 24.

Internal Medicine and Multi-organic Diseases Department, Local Referral Center for Rare Autoimmune Diseases, Montpellier University Hospital, Montpellier F-34000, France; Institut National de la Santé Et de la Rercherche Médicale (INSERM) U1183, Institute for Regenerative Medicine and Biotherapies (IRMB), Montpellier F-34000, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.autrev.2017.11.015DOI Listing
February 2018

Changes in metabolism affect expression of ABC transporters through ERK5 and depending on p53 status.

Oncotarget 2018 Jan 14;9(1):1114-1129. Epub 2017 Dec 14.

Department of Lymphocyte Differentiation, Tolerance and Metabolism: Basis for Immunotherapy, Institut De Médecine Régénératrice Et Biothérapie (IRMB), INSERM, Univ De Montpellier, Montpellier, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.23305DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5787424PMC
January 2018

Association between textural and morphological tumor indices on baseline PET-CT and early metabolic response on interim PET-CT in bulky malignant lymphomas.

Med Phys 2017 Sep 2;44(9):4608-4619. Epub 2017 Aug 2.

Nuclear Medicine Department, Gui de Chauliac University Hospital, 80, Avenue Augustin Fliche, 34295, Montpellier Cedex 5, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mp.12349DOI Listing
September 2017

Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell Lymphoma.

N Engl J Med 2017 09;377(13):1250-1260

From Service d'Hématologie Clinique (S.L.G., T.G.), Service d'Anatomopathologie (A.M.), and Service d'Hématologie Biologique (M.C.B.), Hôtel-Dieu Centre Hospitalier Universitaire (CHU) de Nantes, and Centre de Recherche en Cancérologie et Immunologie (S.L.G., M.C.B.) and Faculté de Médecine (S.L.G.), Université de Nantes, Nantes, Hemato-Oncologie, Assistance Publique-Hôpitaux de Paris (APHP), Hôpital Saint-Louis, Université Diderot Sorbonne Paris-Cité (C.T.), Université Descartes (C.T.), Département d'Hématologie, Faculté de Médecine, Université Paris-Sud (V.R.), Département d'Anatomopathologie (D.C.) and Département d'Hématologie (O.H.), Necker Hospital, APHP, Sorbonne Paris-Cité, and INSERM Unité 1163 et Centre National de la Recherche Scientifique (CNRS) Équipe de Recherche Labellisée 8654, Imagine Institute (O.H.), Paris, Département d'Hématologie, Institut Universitaire du Cancer-Oncopole de Toulouse, Toulouse (L.O.), Service d'Hématologie Clinique et Thérapie Cellulaire, CHU de Bordeaux, Bordeaux (K.B.), Service d'Hématologie et Thérapie Cellulaire, CHU de Tours, Tours (C.D.), Service d'Hématologie, CHU d'Amiens, Amiens (G.D.), INSERM, Gustave Roussy Cancer Campus, Université Paris-Saclay, Villejuif (V.R.), Département d'Hématologie, CHU de Nancy, Nancy (P.F.), INSERM Unité 954, Vandoeuvre (P.F.), Service d'Hématologie Clinique, CHU de Dijon, and INSERM Unité Mixte de Recherche 1231, Dijon (O.C.), Service d'Hématologie, Centre Hospitalier d'Avignon, Avignon (H.Z.), Lymphoid Malignancies Unit, Hôpital Henri Mondor, APHP, Créteil (C.H.), Service d'Hématologie du Centre Hospitalier de Vendée, La Roche-sur-Yon (H.M.), Service Hématologie Clinique (R.H.) and Département d'Hématologie (T.L.), CHU de Rennes, INSERM Unité 917 (R.H.), and INSERM Unité 1236 (T.L.), Rennes, Département d'Hematology, Centre Henri-Becquerel et Université de Normandie Unité 1245, Rouen (F.J., H.T.), Service d'Hématologie Clinique Adulte et de Thérapie Cellulaire, CHU de Clermont-Ferrand et Université Clermont Auvergne, Clermont-Ferrand (O.T.), Service d'Hématologie, Clinique Victor Hugo, Le Mans (K.L.D.), Department of Hematology, Université de Lille, Groupe de Recherche sur les Formes Injectables et les Technologies Associées, and CHU de Lille, Lille (F.M.), Département d'Hématologie Clinique, CHU de Montpellier, CNRS UMR 5235, Montpellier (G.C.), Service d'Oncologie et d'Hématologie, Hôpitaux Universitaires de Strasbourg, Strasbourg (L.-M.F.), INSERM 1209, CNRS UMR 5309, Faculté de Médecine, Université Grenoble Alpes (M.C., R.G.), Institute for Advanced Biosciences (M.C.), and Laboratoire de Génétique Onco-hématologie (M.C.) and Faculté de Médecine (R.G.), CHU de Grenoble Alpes, Grenoble, Service d'Hématologie, Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Pierre-Bénite (G.S.), and Université Claude Bernard Lyon 1 and Cancer Research Center of Lyon, INSERM 1052 CNRS 5286 Lyon, Lyon (G.S.) - all in France; and Département d'Hématologie, Cliniques Universitaires Saint-Luc-Université Catholique de Louvain, Brussels (E.V.D.N.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1701769DOI Listing
September 2017

Obinutuzumab: what is there to learn from clinical trials?

Blood 2017 08 5;130(5):581-589. Epub 2017 Jun 5.

UMR CNRS 7292, Université François Rabelais, Tours, France; and.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2017-03-771832DOI Listing
August 2017

Gota et al. on their article "the pharmacokinetics of Reditux™, a biosimilar of rituximab".

Cancer Chemother Pharmacol 2016 12 17;78(6):1317-1318. Epub 2016 Oct 17.

CNRS, GICC UMR 7292, Université François-Rabelais de Tours, Tours, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-016-3176-6DOI Listing
December 2016

Immune-checkpoint expression in Epstein-Barr virus positive and negative plasmablastic lymphoma: a clinical and pathological study in 82 patients.

Haematologica 2016 08 12;101(8):976-84. Epub 2016 May 12.

Service d'Hématologie, AP-HP, Hôpital Saint-Antoine, Paris, France Centre de Référence des Microangiopathies Thrombotiques, AP-HP, Paris, France UPMC, Université Paris VI, France Inserm U1170, Institut Gustave Roussy, Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2016.141978DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4967577PMC
August 2016

T-cell defect in diffuse large B-cell lymphomas involves expansion of myeloid-derived suppressor cells.

Blood 2016 08 23;128(8):1081-92. Epub 2016 Jun 23.

Pôle Biologie and INSERM, Unité Mixte de Recherche U917, Equipe Labellisée Ligue Contre le Cancer, Rennes, France; Université Rennes 1, Unité Mixte de Recherche U917, Rennes, France; Etablissement Français du Sang Bretagne, Rennes, France;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2015-08-662783DOI Listing
August 2016

Obinutuzumab for relapsed or refractory indolent non-Hodgkin's lymphomas.

Ther Adv Hematol 2016 Apr;7(2):85-93

Département d'Hématologie Clinique, Centre Hospitalier Régional Universitaire, 80 Avenue Augustin Fliche, 34295 Montpellier Cedex 05, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/2040620715622613DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4802503PMC
April 2016

Rationale for optimal obinutuzumab/GA101 dosing regimen in B-cell non-Hodgkin lymphoma.

Haematologica 2016 Feb 11;101(2):226-34. Epub 2015 Dec 11.

Roche Pharmaceutical Research and Early Development, Roche Innovation Center Welwyn, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2015.133421DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4938339PMC
February 2016

Scientific Significance of Clinically Insignificant FcγRIIIa-V158F Polymorphism.

Clin Cancer Res 2016 Feb 18;22(4):787-9. Epub 2015 Dec 18.

Department of Medicine, Division of Oncology, Stanford University, Stanford, California.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-15-2777DOI Listing
February 2016

EZH2 in normal hematopoiesis and hematological malignancies.

Oncotarget 2016 Jan;7(3):2284-96

Department of Biological Hematology, CHU Montpellier, Montpellier, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.6198DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4823035PMC
January 2016

Human Leukemic Cells performing Oxidative Phosphorylation (OXPHOS) Generate an Antioxidant Response Independently of Reactive Oxygen species (ROS) Production.

EBioMedicine 2016 Jan 26;3:43-53. Epub 2015 Nov 26.

INSERM, U1183; Université de Montpellier 1, UFR Medecine, 80, Av. Augustin Fliche, 34295 Montpellier Cedex 5, France; Institute of Regenerative Medicine and Biotherapy (IRMB), CHU Montpellier, Montpellier, 34295, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ebiom.2015.11.045DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4739420PMC
January 2016

Obinutuzumab in hematologic malignancies: lessons learned to date.

Cancer Treat Rev 2015 Nov 14;41(9):784-92. Epub 2015 Jul 14.

Department of Hematology and UMR CNRS-5235, CHU Montpellier, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctrv.2015.07.003DOI Listing
November 2015

High efficiency cell-specific targeting of cytokine activity.

Nat Commun 2014 ;5:3016

1] CNRS UMR 5235, University Montpellier II, Place Eugène Bataillon, 34095 Montpellier, France [2].

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/ncomms4016DOI Listing
October 2015

Identification of Anti-tumor Cells Carrying Natural Killer (NK) Cell Antigens in Patients With Hematological Cancers.

EBioMedicine 2015 Oct 13;2(10):1364-76. Epub 2015 Aug 13.

INSERM U1183, Université de Montpellier, UFR Médecine, Montpellier, France ; Institut for Regenerative Medicine and Biotherapy (IRMB), CHU Montpellier, Montpellier 34295, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ebiom.2015.08.021DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4634619PMC
October 2015

DNA repair in diffuse large B-cell lymphoma: a molecular portrait.

Br J Haematol 2015 Apr 5;169(2):296-9. Epub 2014 Nov 5.

Department of Biological Haematology, CHU Montpellier, Montpellier, France; INSERM U1040, CHU Montpellier, Montpellier, France; UFR de Médecine, University of Montpellier 1, Montpellier, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.13206DOI Listing
April 2015

New anti-CD20 monoclonal antibodies: which is the best?

Leuk Lymphoma 2015 Jan 25;56(1):1-2. Epub 2014 Jun 25.

Hematology Department, CHRU Montpellier , UMR CNRS 5235, Montpellier, France and LabEx MAbImprove, Tours , France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/10428194.2014.904513DOI Listing
January 2015

Circulating miRNA-125b is a potential biomarker predicting response to rituximab in rheumatoid arthritis.

Mediators Inflamm 2014 20;2014:342524. Epub 2014 Mar 20.

Inserm U844, CHU Saint Eloi, Bâtiment INM, 80 Avenue Augustin Fliche, 34295 Montpellier Cedex 5, France ; Université Montpellier I, UFR de Médecine, Boulevard Henri IV, 34090 Montpellier, France ; Clinical Department for Osteoarticular Diseases, CHU Lapeyronie, Avenue Gaston Giraud, 34295 Montpellier, France.

View Article

Download full-text PDF

Source
http://www.hindawi.com/journals/mi/2014/342524/
Publisher Site
http://dx.doi.org/10.1155/2014/342524DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3980876PMC
December 2014

Obinutuzumab: a new class of anti-CD20 monoclonal antibody.

Curr Opin Oncol 2014 Sep;26(5):484-91

aUMR CNRS 5235, Université Montpellier, Montpellier bLabex MAbImprove, Faculté de Médecine de Tours, Tours cDépartement d'Hématologie Clinique, Centre Hospitalier Régional Universitaire (CHRU) de Montpellier, Montpellier, France.

View Article

Download full-text PDF

Source
http://pdfs.journals.lww.com/co-oncology/2014/09000/Obinutuz
Web Search
http://dx.doi.org/10.1097/CCO.0000000000000107DOI Listing
September 2014

Comparison of EBV DNA viral load in whole blood, plasma, B-cells and B-cell culture supernatant.

J Med Virol 2014 May 22;86(5):851-6. Epub 2013 Nov 22.

INSERM U1058, University of Montpellier 1, Montpellier, France; Montpellier Hospital Centre, Institute of Biotherapies Research, Laboratory of Human Rare Circulating Cells, Montpellier, France; Montpellier Hospital Centre, Department of Bacteriology and Virology, Paris, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jmv.23858DOI Listing
May 2014

Obinutuzumab (GA101) plus CHOP or FC in relapsed/refractory follicular lymphoma: results of the GAUDI study (BO21000).

Blood 2013 Aug 10;122(7):1137-43. Epub 2013 Jul 10.

The University of Manchester and Christie National Health Service Foundation Trust, Manchester, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2013-01-481341DOI Listing
August 2013

Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients.

Blood 2012 May 19;119(22):5126-32. Epub 2012 Mar 19.

Hospices Civils de Lyon, Hematologie, Université de Lyon, Unité Mixte de Recherche (UMR) 5239, Centre National de la Recherche Scientifique (CNRS), Pierre-Bénite, France.

View Article

Download full-text PDF

Source
http://www.bloodjournal.org/cgi/doi/10.1182/blood-2012-01-40
Publisher Site
http://dx.doi.org/10.1182/blood-2012-01-404368DOI Listing
May 2012

Model-based design of rituximab dosage optimization in follicular non-Hodgkin's lymphoma.

Br J Clin Pharmacol 2012 Apr;73(4):597-605

Université François Rabelais de Tours, Laboratoire de Pharmacologie-Toxicologie, CHRU Tours, 2 boulevard Tonnellé, Tours Cedex, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1365-2125.2011.04125.xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3376436PMC
April 2012

Clinical radioimmunotherapy--the role of radiobiology.

Nat Rev Clin Oncol 2011 Nov 8;8(12):720-34. Epub 2011 Nov 8.

Direction de la Radioprotection de l'Homme, Institut de Radioprotection et de Sûreté Nucléaire, Fontenay-aux-Roses, F-92262, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrclinonc.2011.160DOI Listing
November 2011

Interindividual variability of response to rituximab: from biological origins to individualized therapies.

Clin Cancer Res 2011 Jan;17(1):19-30

Service d'Hématologie, Centre Hospitalier Universitaire, Université Montpellier I, UMR CNRS5235, Université Montpellier II, France.

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/cgi/doi/10.1158/1078-0
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-10-1292DOI Listing
January 2011

[Monoclonal antibody therapy for non-Hodgkin's lymphoma].

Rev Prat 2010 Jan;60(1):59-63

Service d'hématologie et centre d'Investigation clinique des biothérapies, CHU de Montpellier, 34295 Montpellier.

View Article

Download full-text PDF

Source
January 2010

[Therapeutic monoclonal antibodies in onco-hematology].

Med Sci (Paris) 2009 Dec;25(12):1085-9

Service d'hématologie et biothérapies, Centre d'investigation clinique biothérapies, CHU de Montpellier, 191, avenue du doyen Gaston Giraud, 34295 Montpellier, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1051/medsci/200925121085DOI Listing
December 2009

FCGR3A polymorphism story: a new piece of the puzzle.

Leuk Lymphoma 2009 Sep;50(9):1401-2

Department of Hematology, CHU Montpellier, UMR CNRS 5235 Montpellier, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428190903161109DOI Listing
September 2009

Maintenance therapy for low-grade lymphomas: has the time come?

Curr Opin Oncol 2007 Sep;19(5):425-32

Service d'Hématologie Clinique, Centre Hospitalier Universitaire (CHU) de Montpellier, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CCO.0b013e3282c9ad65DOI Listing
September 2007